ImmunityBio, Inc.
IBRX
Kedudukan dalam Saham
#2231
ImmunityBio, Inc. is a clinical-stage biotechnology firm, founded in 2014 and... ImmunityBio, Inc. is a clinical-stage biotechnology firm, founded in 2014 and based in San Diego, California. The company is focused on developing groundbreaking therapies and vaccines designed to treat a wide array of cancers and infectious diseases. Its innovative approach relies on a comprehensive suite of immunotherapy and cell therapy platforms. These advanced technologies include novel antibody-cytokine fusion proteins, synthetically engineered immunomodulators, cutting-edge vaccine technologies, natural killer (NK) cell therapies, and strategies that harness the adaptive (T-cell) immune system. ImmunityBio currently has several therapeutic candidates in advanced clinical development, with agents undergoing Phase II or III trials. These investigational treatments are aimed at various liquid and solid tumors, such as bladder, pancreatic, and lung cancers, as well as significant infectious pathogens including SARS-CoV-2 and HIV. The company actively engages in strategic partnerships, holding collaboration agreements with esteemed organizations like the National Cancer Institute, the National Institute of Deafness and Communication Disorders, and Amyris, Inc. Additionally, ImmunityBio has secured licensing agreements with numerous entities, including CytRx Corporation, EnGeneIC Pty Limited, GlobeImmune, Inc., Infectious Disease Research Institute, Sanford Health, Shenzhen Beike Biotechnology Co. Ltd., Sorrento Therapeutics, Inc., and Viracta Therapeutics, Inc.
Harga Saham
$8.55
Disegerakkan terakhir: 2026-10-19
Modal Pasaran
$9.06B
Perubahan (1 hari)
-6.84%
Perubahan (1 tahun)
249.08%
Negara
US
Perdagangan ImmunityBio, Inc. (IBRX)
Kategori
Healthcare
Pendapatan untuk ImmunityBio, Inc. (IBRX)
Pendapatan pada Jun 2026 TTM: $-992.58M
Menurut laporan kewangan terkini ImmunityBio, Inc., pendapatan semasa syarikat ialah $-992.58M. Pada tahun 2023, syarikat memperoleh pendapatan sebanyak $-583.89M, penurunan berbanding pendapatan pada tahun 2022 yang berjumlah $-417.29M. Pendapatan yang dipaparkan di halaman ini adalah pendapatan sebelum faedah dan cukai atau dikenali sebagai EBIT.
Sejarah pendapatan bagi ImmunityBio, Inc. dari 2013 hingga 2026
Pendapatan pada akhir setiap tahun
| Tahun | Pendapatan | Ubah |
|---|---|---|
| 2026 (TTM) | $-992.58M | 139.96% |
| 2024 | $-413.65M | -29.16% |
| 2023 | $-583.89M | 39.93% |
| 2022 | $-417.29M | 19.28% |
| 2021 | $-349.84M | 54.77% |
| 2020 | $-226.03M | 243.07% |
| 2019 | $-65.89M | -31.89% |
| 2018 | $-96.73M | -0.19% |
| 2017 | $-96.92M | -20.16% |
| 2016 | $-121.38M | -48.82% |
| 2015 | $-237.18M | 3,718.05% |
| 2014 | $-6.21M | 203.62% |
| 2013 | $-2.05M | 0.00% |
Pendapatan untuk syarikat atau pesaing serupa
| Syarikat | Pendapatan | Perbezaan Pendapatan | Negara |
|---|---|---|---|
| $5.27B | -631.43% |
US
|
|
| $-3.09B | 211.01% |
US
|
|
| $-4.02B | 304.62% |
AU
|
|
| - | - |
CH
|
|
| $1.95B | -296.52% |
NL
|
